<< AHP and LGND are working on drug/s that could eventually make
Premarin all but a dead drug >>
Your discussion of "designer hormones" was interesting, thanks.
<< LGND's pipeline is the deepest I've seen in any biotech I've looked at. Let's just hope it's quality pipe :) >>
I think that LGND is a case where the "sum" is less than "the sum of it's parts". At a $500 million capitalization, LGND seems moderately priced, for a biotech company that doesn't have a commercialized product. But, if you would split LGND into separate pieces, as separate stocks, you'd probably get a significantly higher valuation.
<< Actually I don't right off hand know the details of the AHP agreement so I don't know how much of that LGND would be entitled to. >>
It sure would be nice to know the exact details of the royalties. LGND also has an Estrogen Agonist program with Pfizer, in clinical trials, and has royalties and milestones connected to Pfizer's Droloxifene Osteoporosis drug, in Phase II/III trials.
<< I'll have to admit that Henry most definitely played a part in my decision to invest in LGND. >>
He certainly wouldn't be devoting so much time to ONE biotech stock, if he didn't feel strongly that there was a pot of gold at the end of the "Ligand Rainbow". There are a lot of other fish in the ocean of biotechs. Plus, as discussed, the information about Ligand is impressive.
Good luck, Bob |
